Medicxi’s new €400M fund unites early, late stage investing
In age of megarounds, Medicxi is sticking with its asset-focused approach with its third fund
Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle.
Medicxi III will deploy €400 million ($451.2 million) across all stages of development, from company creation through late-stage clinical assets that have already shown proof of concept.
It follows the firm’s initial